Seoul Pharma Co. Ltd (018680) — Cash Flow-to-Debt Ratio
Seoul Pharma Co. Ltd (018680) has a Cash Flow-to-Debt Ratio of -0.08x as of September 2025, meaning its operating cash flow of ₩-2.66 Billion could theoretically repay 0% of its total liabilities (₩32.70 Billion) in one year. See 018680 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Seoul Pharma Co. Ltd Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Seoul Pharma Co. Ltd across 13 annual periods. Also explore 018680 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Seoul Pharma Co. Ltd (2012–2024)
Year-by-year debt coverage analysis for Seoul Pharma Co. Ltd. For market capitalisation and broader financial context, see Seoul Pharma Co. Ltd stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.10x | ₩-3.01 Billion | ₩31.45 Billion | ▼ -145.0% |
| 2023 | 0.21x | ₩5.26 Billion | ₩24.74 Billion | ▲ +7447.2% |
| 2022 | 0.00x | ₩-78.21 Million | ₩27.01 Billion | ▲ +92.5% |
| 2021 | -0.04x | ₩-1.67 Billion | ₩43.29 Billion | ▼ -124.4% |
| 2020 | 0.16x | ₩5.74 Billion | ₩36.23 Billion | ▲ +129.4% |
| 2019 | 0.07x | ₩2.93 Billion | ₩42.44 Billion | ▲ +326.3% |
| 2018 | -0.03x | ₩-1.23 Billion | ₩40.25 Billion | ▲ +11.3% |
| 2017 | -0.03x | ₩-1.14 Billion | ₩33.08 Billion | ▲ +8.2% |
| 2016 | -0.04x | ₩-1.89 Billion | ₩50.47 Billion | ▼ -229.5% |
| 2015 | 0.03x | ₩1.42 Billion | ₩49.15 Billion | ▼ -6.3% |
| 2014 | 0.03x | ₩1.48 Billion | ₩47.88 Billion | ▲ +384.6% |
| 2013 | -0.01x | ₩-425.00 Million | ₩39.17 Billion | ▼ -104.2% |
| 2012 | 0.26x | ₩9.22 Billion | ₩35.29 Billion | — |